Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 33Burkitt Lymphoma 32Lymphoma 30Leukemia, Myeloid, Acute 29Lymphoma, Non-Hodgkin 28Recurrence 26Breast Neoplasms 26Lymphoma, B-Cell 23Neoplasms 22Myelodysplastic Syndromes 20Lymphoma, Follicular 20Leukemia, Lymphocytic, Chronic, B-Cell 20Hodgkin Disease 17Triple Negative Breast Neoplasms 16Leukemia 16Ovarian Neoplasms 15Hematologic Neoplasms 15Melanoma 14Neuroblastoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Pancreatic Neoplasms 11Leukemia, Biphenotypic, Acute 10Sarcoma 9Neoplasm Metastasis 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myelomonocytic, Chronic 9

Interventions

Gemcitabine 3Cyclophosphamide 3romidepsin 2pembrolizumab 2duvelisib 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Biopsy 2Azacitidine 2tazemetostat 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1ruxolitinib 1ixazomib 1ivarmacitinib 1fludarabine 1etoposide phosphate 1cemiplimab 1cabiralizumab 1belinostat 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Specimen Handling 1Prednisolone 1Photons 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Cyclophosphamide × 90 days × Clear all
NCT07055477 2026-05-22

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
60 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT07535762 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
36 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡